
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7352965/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterology, 2023, 14, 45-51.	1.8	1
2	Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. Liver Cancer, 2023, 12, 19-31.	7.7	5
3	Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 257-273.	17.8	77
4	Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy. Cell Death and Disease, 2022, 13, 143.	6.3	16
5	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. Journal of Hepatology, 2022, 77, 596-606.	3.7	38
6	COVID-19 and liver cancer: lost patients and larger tumours. BMJ Open Gastroenterology, 2022, 9, e000794.	2.7	19
7	CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 2022, 71, 2093-2106.	12.1	66
8	Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nature Cancer, 2022, 3, 386-401.	13.2	126
9	The feasibility and acceptability of a home-based, virtual exercise intervention for older patients with hepatocellular carcinoma: protocol for a non-randomised feasibility study (TELEX-Liver Cancer). Pilot and Feasibility Studies, 2022, 8, .	1.2	2
10	Outcome of liver cancer patients with SARS oVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	3.9	11
11	Signed, SEALed, detected l'm your patient with advanced fibrosis or cirrhosis!. Journal of Hepatology, 2022, , .	3.7	1
12	Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?. Liver Cancer, 2022, 11, 540-557.	7.7	6
13	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. Journal of Hepatology, 2021, 74, 775-782.	3.7	193
14	High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Liver International, 2021, 41, 828-836.	3.9	19
15	Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. Hpb, 2021, 23, 495-505.	0.3	9
16	Hepatocellular carcinoma in non-alcoholic fatty liver disease—a review of an emerging challenge facing clinicians. Hepatobiliary Surgery and Nutrition, 2021, 10, 59-75.	1.5	34
17	Neutrophils induce paracrine telomere dysfunction and senescence in ROSâ€dependent manner. EMBO Journal, 2021, 40, e106048.	7.8	101
18	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. Cancers, 2021, 13, 1412.	3.7	26

#	Article	IF	CITATIONS
19	NAFLD-Associated HCC: Progress and Opportunities. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 223-239.	3.7	33
20	Combined hepatocellularâ€cholangiocarcinoma – More questions than answers. Liver International, 2021, 41, 1186-1188.	3.9	2
21	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. Cell Death and Disease, 2021, 12, 555.	6.3	10
22	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	4.9	36
23	Key features of the environment promoting liver cancer in the absence of cirrhosis. Scientific Reports, 2021, 11, 16727.	3.3	12
24	Cell-free DNA TAPS provides multimodal information for early cancer detection. Science Advances, 2021, 7, eabh0534.	10.3	41
25	A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma. Journal of Visualized Experiments, 2021, , .	0.3	3
26	Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 865-878.	3.7	111
27	HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway. Cancers, 2021, 13, 5079.	3.7	7
28	Mapping of population disparities in the cholangiocarcinoma urinary metabolome. Scientific Reports, 2021, 11, 21286.	3.3	2
29	Characterisation of the Serum Metabolic Signature of Cholangiocarcinoma in a United Kingdom Cohort. Journal of Clinical and Experimental Hepatology, 2020, 10, 17-29.	0.9	12
30	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 167-181.	7.7	28
31	A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification. Journal of Hepatology, 2020, 73, S13-S14.	3.7	4
32	High subcutaneous tissue density correlates negatively with survival in patients with hepatocellular carcinoma. Journal of Hepatology, 2020, 73, S383-S384.	3.7	0
33	Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. CardioVascular and Interventional Radiology, 2019, 42, 1563-1570.	2.0	12
34	The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 371-390.	4.5	71
35	Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 23-30.	3.7	16
36	<p>Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population</p> . Hepatic Medicine: Evidence and Research, 2019, Volume 11, 47-67.	2.5	10

#	Article	IF	CITATIONS
37	From NASH to HCC: current concepts and future challenges. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 411-428.	17.8	872
38	Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy. Journal of Clinical Investigation, 2019, 130, 258-271.	8.2	45
39	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2018, 73, 369-385.	2.9	35
40	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. British Journal of Cancer, 2018, 118, 248-257.	6.4	71
41	Reply to â€~Comment on â€~Circulating Neutrophils in patients with hepatocellular carcinomaâ€: British Journal of Cancer, 2018, 119, 781-782.	6.4	0
42	Liquid biopsy for liver diseases. Gut, 2018, 67, 2204-2212.	12.1	79
43	Opposite effects of a glucokinase activator and metformin on glucoseâ€regulated gene expression in hepatocytes. Diabetes, Obesity and Metabolism, 2017, 19, 1078-1087.	4.4	21
44	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	2.8	43
45	MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports, 2017, 7, 4492.	3.3	193
46	NAFLD—which patients should have hepatocellular carcinoma surveillance?. Hepatobiliary Surgery and Nutrition, 2017, 6, 353-355.	1.5	4
47	Assessment of the Hong Kong Liver Cancer Staging System in Europe. Liver International, 2016, 36, 911-917.	3.9	16
48	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. British Journal of Cancer, 2016, 114, 744-750.	6.4	150
49	Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology, 2016, 6, 186-194.	0.9	13
50	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clinical Gastroenterology and Hepatology, 2016, 14, 875-886.e6.	4.4	217
51	Highâ€resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. International Journal of Cancer, 2016, 138, 206-216.	5.1	45
52	Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2016, 115, 797-804.	6.4	13
53	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2016, 110, hcw151.	0.5	26
54	AISF position paper on liver transplantation and pregnancy. Digestive and Liver Disease, 2016, 48, 860-868.	0.9	20

#	Article	IF	CITATIONS
55	Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. Journal of Hepatology, 2016, 65, 305-313.	3.7	98
56	Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Digestive Diseases and Sciences, 2016, 61, 1234-1245.	2.3	111
57	Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases. Chemical Science, 2016, 7, 2821-2826.	7.4	5
58	Reply to: HCC and liver disease risk in homozygous PNPLA3 p.1148M carriers approach monogenic inheritance. Journal of Hepatology, 2015, 62, 982-983.	3.7	19
59	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. Journal of Clinical Oncology, 2015, 33, 550-558.	1.6	1,810
60	Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis. Journal of Hepatology, 2015, 62, 1296-1303.	3.7	92
61	Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases. Organic and Biomolecular Chemistry, 2015, 13, 5279-5284.	2.8	12
62	DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival. Clinical Cancer Research, 2015, 21, 925-933.	7.0	74
63	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 144-153.	2.5	217
64	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. Journal of Hepatology, 2014, 60, 110-117.	3.7	487
65	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nature Communications, 2014, 5, 4309.	12.8	478
66	Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area― Journal of Hepatology, 2014, 60, 1330-1331.	3.7	1
67	Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. Journal of Hepatology, 2013, 58, 1000-1006.	3.7	50
68	Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1083-1093.	7.3	55
69	Reply:. Hepatology, 2005, 41, 682-683.	7.3	11
70	Targeted Inhibition of the KLF6 Splice Variant, KLF6 SV1, Suppresses Prostate Cancer Cell Growth and Spread. Cancer Research, 2005, 65, 5761-5768.	0.9	151
71	A Germline DNA Polymorphism Enhances Alternative Splicing of the KLF6 Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk. Cancer Research, 2005, 65, 1213-1222.	0.9	202
72	Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1. Cancer Research, 2004, 64, 3885-3891.	0.9	152

#	Article	IF	CITATION
73	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology, 2004, 40, 1047-1052.	7.3	142
74	<i>KLF6</i> , a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. Science, 2001, 294, 2563-2566.	12.6	408
75	The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells. Hepatology, 2000, 31, 95-100.	7.3	26
76	Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. Journal of Hepatology, 2000, 32, 465-472.	3.7	74
77	Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. Journal of Hepatology, 1996, 25, 677-683.	3.7	139
78	In Vitro Cytotoxicity of 150 Chemicals to 3T3-L1 Cells, Assessed by the FRAME Kenacid Blue Method. ATLA Alternatives To Laboratory Animals, 1988, 16, 84-95.	1.0	63
79	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0